AL 794

Drug Profile

AL 794

Alternative Names: AL-794; Influenza virus polymerase PA subunit inhibitor - Alios BioPharma; Influenza virus RNA polymerase inhibitor - Alios BioPharma; JNJ-64155806

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alios BioPharma
  • Class Antivirals
  • Mechanism of Action RNA replicase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 26 Sep 2017 Alios Biopharma completes a phase I safety and pharmacokinetics trial in Healthy volunteers in United Kingdom (PO) (NCT02888327)
  • 31 Aug 2017 Alios Biopharma terminates a phase I trial in Influenza virus infections (In volunteers) in USA as the study stopping rules were met (PO) (NCT03126097)
  • 14 Aug 2017 Elios Biopharma initiates a phase I clinical trial for Influenza virus infections (In volunteers) in United Kingdom (PO, Suspension) (NCT02588521)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top